VYNT News and Press, Vyant Bio Inc. From 08/15/22

CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...

Vyant Bio ( NASDAQ: VYNT ) is scheduled to announce Q2 earnings results on Monday, August 15th, after market close. The consensus EPS Estimate is -$0.15 and the consensus Revenue Estimate is $0.2M (-89.5% Y/Y). For further details see: Vyant Bio Q2 2022 Earnings ...

CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...

Cherry Hill, New Jersey--(Newsfile Corp. - August 3, 2022) - Vyant Bio, Inc. (NASDAQ: VYNT) ("Vyant Bio" or "Company") is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system ("CNS") ...

CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...

Cherry Hill, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...

Vyant Bio, Inc. (VYNT) Q1 2022 Earnings Conference Call May 16, 2022 04:30 PM ET Company Participants Jay Roberts - Chief Executive Officer Andy LaFrence - Chief Financial Officer Robert Fremeau - Chief Scientific Officer Conference Call Participants Ed White - H.C. Wainwright Michael Mortens...

Vyant Bio press release (NASDAQ:VYNT): Q1 GAAP EPS of -$0.32 misses by $0.16. Revenue of $0.31M (+47.6% Y/Y) beats by $0.01M. For further details see: Vyant Bio GAAP EPS of -$0.32 misses by $0.16, revenue of $0.31M beats by $0.01M

Vyant Bio press release (NASDAQ:VYNT): Q1 GAAP EPS of -$0.32 misses by $0.16. Revenue of $0.3M (+200.0% Y/Y) in-line. Shares +1.72% PM. For further details see: Vyant Bio GAAP EPS of -$0.32 misses by $0.16, revenue of $0.3M in-line

Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Financial Highlights CHERRY HILL, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT) is an innovative bi...